VRDN - Company ID 0001590750
The table below shows Viridian Therapeutics, Inc.DE's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $70.85M | $302.00K | $314.00K | $1.77M | $2.96M | $1.05M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $95.31M |
Viridian Therapeutics, Inc.DE reported annual revenue of $70.85M for fiscal year 2025. That is up 23359.9% from $302.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $3.48M (FY 2016) to $70.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $61.08M |
| $95.00M |
| $35.18M |
| $25.80M |
| $13.27M |
| Operating income | -$363.39M | -$299.04M | -$254.45M | -$134.30M | -$79.73M | -$110.38M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$342.60M | -$269.90M | -$237.70M | -$129.90M | -$79.40M | -$110.72M |
| EPS (diluted) | - | - | -$5.31 | -$4.05 | -$6.66 | -$31.13 |